{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:51:00Z","timestamp":1793731860157,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"publisher","award":["TCMF-MP-114-02-01"],"award-info":[{"award-number":["TCMF-MP-114-02-01"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04952-x","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:57:22Z","timestamp":1765547842000},"page":"2037-2044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic outcomes and predictive factors of intradetrusor onabotulinumtoxinA for neurogenic detrusor overactivity (NDO) associated with spinal cord lesion"],"prefix":"10.1007","volume":"58","author":[{"given":"Yi-Hsuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"4","key":"4952_CR1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0090-4295(99)00553-1","volume":"55","author":"KJ Weld","year":"2000","unstructured":"Weld KJ, Dmochowski RR (2000) Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 55(4):490\u2013494","journal-title":"Urology"},{"issue":"2","key":"4952_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jpeds.2014.09.039","volume":"166","author":"KJ Sawin","year":"2015","unstructured":"Sawin KJ, Liu T, Ward E et al (2015) The National Spina Bifida Patient Registry: profile of a large cohort of participants from the first 10 clinics. J Pediatr 166(2):444\u2013450","journal-title":"J Pediatr"},{"issue":"4","key":"4952_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/nau.23957","volume":"38","author":"C Joussain","year":"2019","unstructured":"Joussain C, Levy J, Charlanes A et al (2019) Urological dysfunction in patients with hereditary spastic paraplegia. Neurourol Urodyn 38(4):1081\u20131085","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"4952_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5435\/JAAOS-D-21-00873","volume":"30","author":"EO Kuris","year":"2022","unstructured":"Kuris EO, Alsoof D, Osorio C et al (2022) Bowel and bladder care in patients with spinal cord injury. J Am Acad Orthop Surg 30(6):263\u2013272","journal-title":"J Am Acad Orthop Surg"},{"issue":"7","key":"4952_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1474-4422(15)00070-8","volume":"14","author":"JN Panicker","year":"2015","unstructured":"Panicker JN, Fowler CJ, Kessler TM (2015) Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol 14(7):720\u2013732","journal-title":"Lancet Neurol"},{"issue":"5","key":"4952_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-0040-1713876","volume":"40","author":"JN Panicker","year":"2020","unstructured":"Panicker JN (2020) Neurogenic bladder: epidemiology, diagnosis, and management. Semin Neurol 40(5):569\u2013579","journal-title":"Semin Neurol"},{"issue":"12","key":"4952_CR7","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00415-016-8212-2","volume":"263","author":"KI Tudor","year":"2016","unstructured":"Tudor KI, Sakakibara R, Panicker JN (2016) Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol 263(12):2555\u20132564","journal-title":"J Neurol"},{"issue":"8","key":"4952_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/nau.70136","volume":"44","author":"R Takahashi","year":"2025","unstructured":"Takahashi R, Imada K, Maki T (2025) Comparison of the efficacy of vibegron and fesoterodine for neurogenic detrusor overactivity in individuals with spinal cord lesion: a single-center prospective randomized crossover trial. Neurourol Urodyn 44(8):1545\u20131552","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"4952_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.eururo.2007.09.034","volume":"53","author":"G Del Popolo","year":"2008","unstructured":"Del Popolo G, Filocamo MT, Li Marzi V et al (2008) Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol 53(5):1013\u20131019","journal-title":"Eur Urol"},{"issue":"4","key":"4952_CR10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","volume":"45","author":"A Reitz","year":"2004","unstructured":"Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45(4):510\u2013515","journal-title":"Eur Urol"},{"key":"4952_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14010035","author":"SF Chen","year":"2022","unstructured":"Chen SF, Jiang YH, Jhang JF et al (2022) Satisfaction with Detrusor OnabotulinumtoxinA injections and conversion to other bladder management in patients with chronic spinal cord injury. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins14010035","journal-title":"Toxins (Basel)"},{"issue":"4","key":"4952_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.juro.2018.10.012","volume":"201","author":"M Baron","year":"2019","unstructured":"Baron M, Peyronnet B, Auble A et al (2019) Long-term discontinuation of botulinum toxin A intradetrusor injections for neurogenic detrusor overactivity: a multicenter study. J Urol 201(4):769\u2013776","journal-title":"J Urol"},{"issue":"3","key":"4952_CR13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.eururo.2016.03.052","volume":"70","author":"L Leitner","year":"2016","unstructured":"Leitner L, Guggenbuhl-Roy S, Knupfer SC et al (2016) More than 15 years of experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol 70(3):522\u2013528","journal-title":"Eur Urol"},{"issue":"6","key":"4952_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41393-024-00992-9","volume":"62","author":"S Vaheb","year":"2024","unstructured":"Vaheb S, Mokary Y, Ghoshouni H et al (2024) Onabotulinum toxin A improves neurogenic detrusor overactivity following spinal cord injury: a systematic review and meta-analysis. Spinal Cord 62(6):285\u2013294","journal-title":"Spinal Cord"},{"issue":"5","key":"4952_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1097\/JU.0000000000002239","volume":"206","author":"DA Ginsberg","year":"2021","unstructured":"Ginsberg DA, Boone TB, Cameron AP et al (2021) The AUA\/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. J Urol 206(5):1106\u20131113","journal-title":"J Urol"},{"issue":"1","key":"4952_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147137","volume":"11","author":"SM Hsiao","year":"2016","unstructured":"Hsiao SM, Lin HH, Kuo HC (2016) Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome. PLoS ONE 11(1):e0147137","journal-title":"PLoS ONE"},{"issue":"4","key":"4952_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.juro.2018.05.006","volume":"200","author":"B Peyronnet","year":"2018","unstructured":"Peyronnet B, Even A, Capon G et al (2018) Intradetrusor injections of botulinum toxin A in adults with spinal dysraphism. J Urol 200(4):875\u2013880","journal-title":"J Urol"},{"key":"4952_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.urology.2019.08.054","volume":"135","author":"M Abrar","year":"2020","unstructured":"Abrar M, Stroman L, Malde S et al (2020) Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder. Urology 135:32\u201337","journal-title":"Urology"},{"issue":"6","key":"4952_CR19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.urology.2014.09.001","volume":"84","author":"SW Kim","year":"2014","unstructured":"Kim SW, Choi JH, Lee YS et al (2014) Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. Urology 84(6):1480\u20131484","journal-title":"Urology"},{"issue":"2","key":"4952_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/nau.22925","volume":"36","author":"YH Jiang","year":"2017","unstructured":"Jiang YH, Kuo HC (2017) Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. Neurourol Urodyn 36(2):338\u2013343","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"4952_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/nau.22642","volume":"34","author":"DJ Osborn","year":"2015","unstructured":"Osborn DJ, Kaufman MR, Mock S et al (2015) Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn 34(7):675\u2013678","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"4952_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60(4):742\u2013750","journal-title":"Eur Urol"},{"issue":"6","key":"4952_CR23","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V et al (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 187(6):2131\u20132139","journal-title":"J Urol"},{"issue":"6","key":"4952_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/bju.13976","volume":"120","author":"M Koschorke","year":"2017","unstructured":"Koschorke M, Leitner L, Sadri H et al (2017) Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? BJU Int 120(6):848\u2013854","journal-title":"BJU Int"},{"issue":"2","key":"4952_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/JU.0000000000000525","volume":"203","author":"L Mateu Arrom","year":"2020","unstructured":"Mateu Arrom L, Mayordomo Ferrer O, Sabiote Rubio L et al (2020) Treatment response and complications after intradetrusor OnabotulinumtoxinA injection in male patients with idiopathic overactive bladder syndrome. J Urol 203(2):392\u2013397","journal-title":"J Urol"},{"key":"4952_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","volume":"123","author":"NA Faure Walker","year":"2019","unstructured":"Faure Walker NA, Syed O, Malde S et al (2019) Onabotulinum toxin A injections in men with refractory idiopathic detrusor overactivity. Urology 123:242\u2013246","journal-title":"Urology"},{"issue":"6","key":"4952_CR27","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K et al (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 185(6):2229\u20132235","journal-title":"J Urol"},{"issue":"7","key":"4952_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159307","volume":"11","author":"T Cheng","year":"2016","unstructured":"Cheng T, Shuang WB, Jia DD et al (2016) Efficacy and safety of OnabotulinumtoxinA in patients with neurogenic detrusor overactivity: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 11(7):e0159307","journal-title":"PLoS ONE"},{"issue":"1","key":"4952_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.juro.2018.07.066","volume":"201","author":"R Khavari","year":"2019","unstructured":"Khavari R, Elias SN, Pande R et al (2019) Higher neural correlates in patients with multiple sclerosis and neurogenic overactive bladder following treatment with intradetrusor injection of OnabotulinumtoxinA. J Urol 201(1):135\u2013140","journal-title":"J Urol"},{"issue":"3","key":"4952_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/nau.22394","volume":"33","author":"SM Hsiao","year":"2014","unstructured":"Hsiao SM, Lin HH, Kuo HC (2014) Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. Neurourol Urodyn 33(3):331\u2013334","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"4952_CR31","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/nau.21150","volume":"30","author":"I Makovey","year":"2011","unstructured":"Makovey I, Davis T, Guralnick ML et al (2011) Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn 30(8):1538\u20131540","journal-title":"Neurourol Urodyn"},{"key":"4952_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214419","author":"S Markopoulou","year":"2022","unstructured":"Markopoulou S, Vardouli L, Dimitriadis F et al (2022) Effect of bladder injection of OnabotulinumtoxinA on the central expression of genes associated with the control of the lower urinary tract: a study in normal rats. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232214419","journal-title":"Int J Mol Sci"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04952-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04952-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04952-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:41:14Z","timestamp":1779370874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04952-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4952"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04952-x","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study had approved by the Ethics Committee of Buddhist Tzu Chi Medical Foundation and Hualien Tzu Chi Hospital, coded: 114-230-B, Dated November 10, 2025.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB"}}]}}